Comparison

mAbMods™ Anti-Mouse CD279 (PD-1) - Fc muted™ (D265A) - Custom

Item no. LEIN-P503-Custom
Manufacturer Leinco Technologies
Amount Custom
Quantity options 1 mg 100 mg 25 mg 5 mg 50 mg Custom
Category
Type Antibody Monoclonal
Applications WB, FA, other, IV
Clone RMP1-14-mAbMods (D265A)
Specific against other
ECLASS 10.1 42030590
ECLASS 11.0 42030590
UNSPSC 12352203
Available
Product Description
This anti-PD1 antibody is a recombinant chimeric version of the original clone RMP1-14 antibody. The variable domain sequences are identical to the original clone RMP1-14; however, the constant region sequences have been switched from rat IgG2a to mouse IgG2a. In this Fc Muted™ format, mutations (D265A) have been introduced that reduce or eliminate Fc-mediated Antibody-Dependent Cellular Phagocytosis (ADCP) and Antibody-Dependent Cellular Cytotoxicity (ADCC).

PD-1 is a 50-55 kD member of the B7 Ig superfamily. PD-1 is also a member of the extended CD28/CTLA-4 family of T cell regulators and is suspected to play a role in lymphocyte clonal selection and peripheral tolerance. The ligands of PD-1 are PD-L1 and PD-L2, and are also members of the B7 Ig superfamily. PD-1 and its ligands negatively regulate immune responses. PD-L1, or B7-Homolog 1, is a 40 kD type I transmembrane protein that has been reported to costimulate T cell growth and cytokine production. The interaction of PD-1 with its ligand PD-L1 is critical in the inhibition of T cell responses that include T cell proliferation and cytokine production. PD-L1 has increased expression in several cancers. Inhibition of the interaction between PD-1 and PD-L1 can serve as an immune checkpoint blockade by improving T-cell responses In vitro and mediating preclinical antitumor activity. Within the field of checkpoint inhibition, combination therapy using anti-PD1 in conjunction with anti-CTLA4 has significant therapeutic potential for tumor treatments. PD-L2 is a 25 kD type I transmembrane ligand of PD-1. Via PD-1, PD-L2 can serve as a co-inhibitor of T cell functions. Regulation of T cell responses, including enhanced T cell proliferation and cytokine production, can result from mAbs that block the PD-L2 and PD-1 interaction.
Target
PD-1
Antigen Distribution
PD-1 is expressed on a subset of CD4-CD8- thymocytes, and on activated T and B cells.
Concentration
≥1.0 mg/ml
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Shipping Conditions
2-8°C Wet Ice
Storage and Stability
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: Custom
Available: In stock
available

Delivery expected until 12/13/2024 

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close